OPEN ACCESS Freely available online

ISSN: 2167-0897
Journal of
Neonatal Biology

Opinion Article

Early Intervention and Management of Neonatal Adrenoleukodystrophy (NALD): Strategies for Improved Outcomes

James Reynolds*

Department of Neonatology, University of Washington, Washington, USA

DESCRIPTION

Neonatal Adrenoleukodystrophy (NALD) is a rare genetic disorder that affects infants and has profound implications for their development and well-being. It is part of a group of disorders known as Peroxisomal Biogenesis Disorders (PBDs), which are characterized by impaired peroxisome function.

NALD is caused by mutations in genes involved in peroxisome biogenesis, specifically the *PEX* genes. Peroxisomes are cell organelles responsible for various metabolic processes, including the breakdown of Very Long-Chain Fatty Acids (VLCFAs). The impaired peroxisome function leads to the accumulation of VLCFAs, primarily in the brain, adrenal glands, and liver.

The symptoms of NALD usually become apparent during the neonatal period or early infancy. Which affects the central nervous system, leading to neurodevelopmental delays and progressive deterioration of motor skills. Infants may experience muscle weakness, poor muscle tone (hypotonia), and difficulty with movement and coordination. Seizures and intellectual disability are also common.

It can cause vision and hearing problems. Infants may develop visual abnormalities, including retinal degeneration and impaired color vision. Hearing loss, ranging from mild to severe, may also be present. The adrenal glands, responsible for producing hormones such as cortisol, are affected in NALD. Adrenal insufficiency can lead to symptoms such as fatigue, poor weight gain, vomiting, and electrolyte imbalances. NALD can result in liver abnormalities, including hepatomegaly (enlarged liver), jaundice, and impaired liver function. Infants may experience poor feeding, failure to thrive, and elevated liver enzymes.

Diagnosing NALD typically involves a combination of clinical evaluation, biochemical testing, and genetic analysis. Blood tests can reveal elevated levels of VLCFAs, as well as abnormalities in other metabolic markers. Genetic testing, such as sequencing the PEX genes, can confirm the diagnosis by identifying specific mutations associated with NALD.

Early diagnosis of NALD is crucial to initiate appropriate interventions and management strategies. Unfortunately, NALD is a progressive disorder with no cure currently available. However, supportive care and therapies can help manage the symptoms and improve the quality of life for affected infants.

Treatment with medications such as adrenal hormone replacement therapy can help manage adrenal insufficiency and stabilize hormone levels. Seizure medications may be prescribed if seizures occur. Infants with NALD may require specialized diets or nutritional supplements to address feeding difficulties and ensure adequate growth and development. These therapies can help optimize motor skills, enhance muscle strength, and improve overall mobility. Early intervention programs may also provide developmental support tailored to the specific needs of the infant.

Regular assessments by ophthalmologists and audiologists are necessary to monitor and address any vision or hearing impairments. Assistive devices, such as hearing aids or visual aids, may be recommended to enhance sensory function. As NALD is a progressive disorder with no cure, palliative care becomes an essential component of management. Palliative care focuses on improving the quality of life for both the infant and their family, providing support, pain management, and emotional and psychological support.

Living with NALD can present significant challenges for both the affected infants and their families. It is crucial for families to have access to support networks, such as support groups and organizations specializing in rare genetic disorders. These resources can provide a sense of community, information sharing, and emotional support to help families navigate the complexities of NALD. Advancements in medical science continue to shed light on NALD and offer hope for potential treatments in the future. Clinical trials and studies are underway to explore novel therapeutic approaches, including gene therapy and targeted interventions to improve peroxisome function.

Correspondence to: James Reynolds, Department of Neonatology, University of Washington, Washington, USA, E-mail: jamy78@rey.EDU

Received: 26-Apr-2023, Manuscript No. JNB-23-21535; **Editor assigned:** 28-Apr-2023, Pre QC No. JNB-23-21535 (PQ); **Reviewed:** 15-May-2023, QC No. JNB-23-21535; **Revised:** 22-May-2023, Manuscript No. JNB-23-21535 (R); **Published:** 30-May-2023, DOI: 10.35248/2167-0897.23.12.413.

Citation: Reynolds J (2023) Early Intervention and Management of Neonatal Adrenoleukodystrophy (NALD): Strategies for Improved Outcomes. J Neonatal Biol. 12:413 .